Comparing the current results to its competitors, Nanobiotix S A reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Nanobiotix S A 's competitors' average revenue growth of 21.98 %, achieved in the same quarter.
Nanobiotix S A 's Comment on Competition and Industry Peers
The company’s product candidate JNJ-1900 (NBTXR3) faces competition from companies developing therapies with similar modes of action. Competitors may possess greater financial resources and expertise in research, development, clinical trials, manufacturing, and marketing, potentially enabling faster development and commercialization. Competition also exists in recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Smaller or early-stage companies may be significant competitors, particularly through collaborations with established firms. Key competitive factors include efficacy, safety, convenience, price, and reimbursement availability. The company must protect its proprietary technology and faces risks if competitors develop more effective or safer products or achieve regulatory approvals more rapidly. The company has not established commercial infrastructure in the U.S. or EU but granted exclusive commercialization rights to Johnson & Johnson under the Janssen Agreement as of July 2023.
April 30, 2025
Overview of NBTXR3 Phase 1 Study in Pancreatic CancerNanobiotix, a late-clinical stage biotechnology company, has recently announced the completion of its Phase 1 study evaluating JNJ-1900, also known as NBTXR3, in patients with locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC). The results of this study represent a significant advancement in the application of nanoparticle-based therapies, aimed at expanding treatment possibilities for patients facing this aggressive form of cancer.The study was conducted at The University of Texas MD Anderson Cancer Center, a leading institution known for its focus on innovative cancer therapies and research. The principal inves...
January 21, 2025
In a landscape riddled with challenges and fierce competition, the battle against advanced non-small cell lung cancer (NSCLC) takes a promising turn with a novel therapeutic approach spearheaded by NANOBIOTIX. On January 21, 2025, the biotech company announced a significant milestone in oncology research the first patient has been dosed in their groundbreaking Phase 2 study known as CONVERGE. This randomized controlled trial is evaluating the innovative therapeutic agent JNJ-1900 (NBTXR3) in individuals grappling with Stage 3 unresectable NSCLC.NANOBIOTIX, a visionary company at the forefront of nanoparticle-based therapies, aims to revolutionize cancer treatment by harnessing the unique properties of nanopa...
June 2, 2024
Nanobiotix, a leading biotechnology company, has recently announced compelling new data for its nanoparticle-based therapeutic approach, NBTXR3, in the treatment of advanced solid and metastatic tumors. The company presented the findings from Study 1100, a US Phase 1 study, at the prestigious 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO 2024), highlighting disease control and tumor response in patients treated with radiotherapy-activated NBTXR3 and anti-PD-1 immune checkpoint inhibitors. Additionally, Nanobiotix received FDA approval for a randomized Phase 2 study evaluating NBTXR3 in patients with stage 3, unresectable non-small cell lung cancer (NSCLC). These developments signify...
May 28, 2024
for CSIMarket.com NANOBIOTIX, a late-clinical-stage biotechnology company, has recently unveiled significant findings from their ongoing Phase 1 study, known as Study 1100, at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO). This study evaluates the efficacy of NBTXR3 followed by anti-PD-1 therapy in patients with recurrent or metastatic head and neck cancer. The presentation of these data underscores the potential of nanoparticle-based therapeutic approaches in expanding treatment possibilities for cancer patients. Study Design and s Study 1100 is a Phase 1 study conducted in the United States, focusing on patients with recurrent or metastatic head and neck cancer. The stu...
May 21, 2024
Nanobiotix, a late-clinical stage biotechnology company, is revolutionizing cancer treatment and addressing major diseases through nanoparticle-based therapeutic approaches. The company recently unveiled updates to its corporate strategy, emphasizing long-term growth opportunities following significant progress in the co-development and global commercialization of its flagship therapeutic candidate, NBTXR3. This article delves into the groundbreaking advancements achieved by Nanobiotix, highlighting the potential impact on the field of oncology and its broader implications for patients worldwide.Nanobiotix s Strategic Collaborations:Nanobiotix s collaborative efforts have been instrumental in propelling the ...
December 26, 2023
Nanobiotix s Groundbreaking Cancer Treatment, NBTXR3, Gains Momentum in Asian MarketsParis and Cambridge, Mass. - In a significant development, Nanobiotix, a renowned biotechnology company focused on advancing innovative physics-based approaches for cancer treatment, has announced that its strategic partner, LianBio, has assigned its development and commercialization rights for NBTXR3, a potential first-in-class radioenhancer, to Janssen Pharmaceutica NV (Janssen), a subsidiary of Johnson and Johnson. This agreement covers exclusive rights for China, South Korea, Singapore, and Thailand, signaling a major breakthrough for cancer patients in these regions.NBTXR3, developed by Nanobiotix, has shown tremendous ...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
Sources:
Nanobiotix S a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nanobiotix S a versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
